SEC Info - Natus Medical Inc. - ‘8-K’ for 1/10/22

SEC Info℠

Home

Help

Please Sign In

Natus Medical Inc. – ‘8-K’ for 1/10/22

On: Monday, 1/10/22, at 4:02pm ET · For: 1/10/22 · Accession #: 878526-22-17 · File #: 0-33001

  As Of               Filer                 Filing    For·On·As Docs:Size

 1/10/22  Natus Medical Inc.                8-K:2,9     1/10/22   11:196K

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     27K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     11K 
 6: R1          Cover Page Document                                 HTML     46K 
 9: XML         IDEA XML File -- Filing Summary                      XML     11K 
 7: XML         XBRL Instance -- ntus-20220110_htm                   XML     21K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      6K 
 4: EX-101.LAB  XBRL Labels -- ntus-20220110_lab                     XML     67K 
 5: EX-101.PRE  XBRL Presentations -- ntus-20220110_pre              XML     33K 
 3: EX-101.SCH  XBRL Schema -- ntus-20220110                         XSD     10K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               11±    17K 
11: ZIP         XBRL Zipped Folder -- 0000878526-22-000017-xbrl      Zip     14K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C:

ntus-20220110

i 0000878526 i false00008785262022-01-102022-01-10

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (date of earliest event reported): i January 10, 2022

i Natus Medical Incorporated

(Exact name of registrant as specified in its charter)

i 000-33001

(Commission File Number)



i Delaware						i 77-0154833
(State or other jurisdiction of Incorporation)						(I.R.S. Employer Identification No.)

i 6701 Koll Center Parkway, Suite 120

i Pleasanton, i CA i 94566

(Address of principal executive offices) (Zip Code)

i 925- i 223-6700

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


			i ☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


			i ☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


			i ☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


			i ☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
i Common Stock, $0.001 par value per share	i NTUS	i The Nasdaq Stock Market LLC
		(The Nasdaq Global Market)


Item 2.02.			Results of Operations and Financial Condition

On January 10, 2022, Natus Medical Incorporated (the “Company”) issued a press release announcing preliminary 2021 fourth quarter and full year results.

The information in this Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.


Item 9.01.			Financial Statements and Exhibits

(d) Exhibits.


Exhibit No.						Description
99.1						Press release dated January 10, 2022.
104						The cover page from this Current Report on Form 8-K, formatted in Inline XBRL (included as Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

NATUS MEDICAL INCORPORATED

(Registrant)

Dated: January 10, 2022

By:

/s/ B. Drew Davies

Executive Vice President and Chief Financial Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	1/10/22	None on these Dates
		List all Filings

2 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 6/02/22  Natus Medical Inc.                DEFM14A                1:4.1M                                   Broadridge Fin’l So… Inc
 5/23/22  Natus Medical Inc.                PREM14A     5/23/22    2:2.4M                                   Broadridge Fin’l So… Inc

↑Top

Filing Submission 0000878526-22-000017 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)